Literature DB >> 20823998

Markers of Blood Cell Activation and Complement Activation in Factor VIII and von Willebrand Factor Concentrates.

Martin F Brodde1, Beate E Kehrel.   

Abstract

BACKGROUND: Preparations of commercially available clotting factor VIII are complex protein mixtures. Most of them contain either von Willebrand factor or human serum albumin as stabilizers. The aim of the study was to quantify further proteins in twelve concentrates either of recombinant origin or derived from human plasma.
METHODS: Proteins were separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Some proteins were quantified by ELISA.
RESULTS: Recombinant clotting factor preparations showed fewer protein spots in the 2D-PAGE, than plasma-derived preparations. Proteins identified in some of the plasma-derived concentrates included up to 90 ng/IU of the anaphylatoxin C3a, up to 40 ng/IU of the platelet a-granule protein thrombospondin-1, up to 0.85 ng/IU of the platelet a-granule protein platelet factor 4, 3.5 ng/IU myeloperoxidase secreted by leukocytes and up to 0.05 ng/IU of the leukocyte-secreted protein a-defensin. The protein content differed between concentrates from different manufacturers.
CONCLUSIONS: The origin of the plasma used to prepare the factor concentrates might influence the protein impurities in these products. It is unknown whether the impurities observed have long-term consequences for chronic inflammatory conditions.

Entities:  

Year:  2010        PMID: 20823998      PMCID: PMC2928838          DOI: 10.1159/000316908

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  54 in total

1.  Factor VIII heavy chain polypeptides in plasma and concentrates.

Authors:  G Kemball-Cook; S A Bevan; T W Barrowcliffe
Journal:  Br J Haematol       Date:  1990-09       Impact factor: 6.998

2.  Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder.

Authors:  B Kehrel; L Balleisen; R Kokott; R Mesters; W Stenzinger; K J Clemetson; J van de Loo
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

Review 3.  Degradation products of factor VIII which can lead to increased immunogenicity.

Authors:  D Josić; A Buchacher; C Kannicht; Y P Lim; K Löster; K Pock; S Robinson; H Schwinn; M Stadler
Journal:  Vox Sang       Date:  1999       Impact factor: 2.144

4.  Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages.

Authors:  Oliver Soehnlein; Ylva Kai-Larsen; Robert Frithiof; Ole E Sorensen; Ellinor Kenne; Karin Scharffetter-Kochanek; Einar E Eriksson; Heiko Herwald; Birgitta Agerberth; Lennart Lindbom
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

5.  Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.

Authors:  James G Clifton; Feilei Huang; Spomenka Kovac; Xinli Yang; Douglas C Hixson; Djuro Josic
Journal:  Electrophoresis       Date:  2009-10       Impact factor: 3.535

Review 6.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

7.  Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy.

Authors:  S M Siboni; P M Mannucci; A Gringeri; M Franchini; A Tagliaferri; M Ferretti; F C Tradati; E Santagostino; S von Mackensen
Journal:  J Thromb Haemost       Date:  2009-02-12       Impact factor: 5.824

Review 8.  Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease.

Authors:  Sanjeev Sirpal
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

9.  Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase.

Authors:  Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

Review 10.  Immunomodulatory properties of defensins and cathelicidins.

Authors:  D M E Bowdish; D J Davidson; R E W Hancock
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

View more
  2 in total

1.  Cellular Stress Induced by Plasma-Derived Factor VIII Products.

Authors:  Martin Brodde; Anja Müller; Beate Kehrel
Journal:  Transfus Med Hemother       Date:  2014-02-17       Impact factor: 3.747

2.  Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Authors:  Anne Bertling; Martin F Brodde; Mayken Visser; Janina Treffon; Michelle Fennen; Anke C Fender; Reinhard Kelsch; Beate E Kehrel
Journal:  Transfus Med Hemother       Date:  2017-08-11       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.